Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
Authors
Keywords
-
Journal
mAbs
Volume 9, Issue 5, Pages 831-843
Publisher
Informa UK Limited
Online
2017-04-19
DOI
10.1080/19420862.2017.1319023
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
- (2016) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
- (2016) Magdalena Malm et al. mAbs
- The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
- (2016) Christophe Le Clorennec et al. Oncotarget
- HER3/ErbB3, an emerging cancer therapeutic target
- (2015) Ningyan Zhang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
- (2015) Georgina Meneses-Lorente et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
- (2015) Sangwon Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular architecture of the ErbB2 extracellular domain homodimer
- (2015) Shi Hu et al. Oncotarget
- Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
- (2015) Nadège Gaborit et al. Human Vaccines & Immunotherapeutics
- The promise of anti-ErbB3 monoclonals as new cancer therapeutics
- (2015) Luigi Aurisicchio et al. Oncotarget
- Regulation of ERBB3/HER3 signaling in cancer
- (2015) Kalpana Mujoo et al. Oncotarget
- Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
- (2015) Yassamine Lazrek et al. NEOPLASIA
- Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway
- (2014) Xiaoyu Wu et al. MEDICAL ONCOLOGY
- The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
- (2014) Z Huang et al. ONCOGENE
- HER3, serious partner in crime
- (2014) Arjan Kol et al. PHARMACOLOGY & THERAPEUTICS
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
- (2013) C. Mirschberger et al. CANCER RESEARCH
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
- (2013) A. P. Garner et al. CANCER RESEARCH
- erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions
- (2013) M. P. Steinkamp et al. MOLECULAR AND CELLULAR BIOLOGY
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
- (2012) Y. Zhou et al. MOLECULAR CANCER THERAPEUTICS
- Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification
- (2011) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Mechanisms of resistance to HER family targeting antibodies
- (2010) Tim J. Kruser et al. EXPERIMENTAL CELL RESEARCH
- A human scFv antibody generation pipeline for proteome research
- (2010) Michael Hust et al. JOURNAL OF BIOTECHNOLOGY
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
- (2010) Dhara N. Amin et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- The epidermal growth factor receptor family: Biology driving targeted therapeutics
- (2008) M. J. Wieduwilt et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Interaction of antibodies with ErbB receptor extracellular regions
- (2008) Karl R. Schmitz et al. EXPERIMENTAL CELL RESEARCH
- Ligand-induced ErbB receptor dimerization
- (2008) Mark A. Lemmon EXPERIMENTAL CELL RESEARCH
- Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice
- (2008) Dafne Müller et al. JOURNAL OF IMMUNOLOGICAL METHODS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now